Compare Stocks: NGNE, HRMY, IOVA, and RAPP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRMY Harmony Biosciences	$35.24 -1.7%	$34.48	$25.52 ▼ $40.87	$2.04B	0.96	830,829 shs	604,885 shs
IOVA Iovance Biotherapeutics	$4.07 -13.2%	$4.31	$1.76 ▼ $5.64	$1.82B	0.71	16.11 million shs	19.91 million shs
NGNE Neurogene	$32.89 -2.1%	$32.42	$15.93 ▼ $43.66	$519.72M	1.7	255,989 shs	162,880 shs
RAPP Rapport Therapeutics	$40.98 -4.2%	$39.35	$13.62 ▼ $44.28	$1.96B	0.97	376,076 shs	240,878 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRMY Harmony Biosciences	0.00%	-0.23%	-5.42%	+10.71%	-0.68%
IOVA Iovance Biotherapeutics	0.00%	-18.44%	-5.57%	+19.71%	+52.43%
NGNE Neurogene	0.00%	-5.76%	-6.93%	+22.50%	+50.39%
RAPP Rapport Therapeutics	0.00%	+0.74%	+5.16%	+20.92%	+176.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRMY Harmony Biosciences	$35.24 -1.7%	$34.48	$25.52 ▼ $40.87	$2.04B	0.96	830,829 shs	604,885 shs
IOVA Iovance Biotherapeutics	$4.07 -13.2%	$4.31	$1.76 ▼ $5.64	$1.82B	0.71	16.11 million shs	19.91 million shs
NGNE Neurogene	$32.89 -2.1%	$32.42	$15.93 ▼ $43.66	$519.72M	1.7	255,989 shs	162,880 shs
RAPP Rapport Therapeutics	$40.98 -4.2%	$39.35	$13.62 ▼ $44.28	$1.96B	0.97	376,076 shs	240,878 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRMY Harmony Biosciences	0.00%	-0.23%	-5.42%	+10.71%	-0.68%
IOVA Iovance Biotherapeutics	0.00%	-18.44%	-5.57%	+19.71%	+52.43%
NGNE Neurogene	0.00%	-5.76%	-6.93%	+22.50%	+50.39%
RAPP Rapport Therapeutics	0.00%	+0.74%	+5.16%	+20.92%	+176.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRMY Harmony Biosciences	2.50	Moderate Buy	$42.63	20.96% Upside
IOVA Iovance Biotherapeutics	2.30	Hold	$8.43	107.09% Upside
NGNE Neurogene	3.00	Buy	$84.83	157.93% Upside
RAPP Rapport Therapeutics	2.92	Moderate Buy	$57.86	41.18% Upside

Current Analyst Ratings Breakdown

Latest NGNE, HRMY, IOVA, and RAPP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$50.00 ➝ $51.00
7/28/2026	RAPP Rapport Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
7/17/2026	NGNE Neurogene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RAPP Rapport Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
7/16/2026	RAPP Rapport Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
7/13/2026	HRMY Harmony Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/2/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/30/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$30.00 ➝ $36.00
6/24/2026	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/24/2026	RAPP Rapport Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$52.00

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRMY Harmony Biosciences	$868.45M	2.35	$3.18 per share	11.08	$15.11 per share	2.33
IOVA Iovance Biotherapeutics	$263.50M	6.90	N/A	N/A	$1.76 per share	2.31
NGNE Neurogene	$930K	558.78	N/A	N/A	$17.10 per share	1.92
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$10.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRMY Harmony Biosciences	$158.69M	$2.48	14.21	9.11	0.33	16.20%	17.19%	11.99%	8/4/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.95	N/A	N/A	N/A	-123.92%	-50.17%	-38.77%	8/6/2026 (Estimated)
NGNE Neurogene	-$90.35M	-$4.55	N/A	N/A	N/A	N/A	-37.88%	-34.70%	8/10/2026 (Estimated)
RAPP Rapport Therapeutics	-$111.48M	-$2.60	N/A	N/A	N/A	N/A	-24.78%	-23.44%	8/6/2026 (Estimated)

Latest NGNE, HRMY, IOVA, and RAPP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	NGNE Neurogene	-$1.40	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1331	N/A	N/A	N/A	$87.67 million	N/A
8/6/2026	Q2 2026	RAPP Rapport Therapeutics	-$0.9631	N/A	N/A	N/A	$2.22 million	N/A
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	N/A	N/A	N/A	$250.77 million	N/A
5/12/2026	Q1 2026	NGNE Neurogene	-$1.2963	-$1.39	-$0.0938	-$1.39	N/A	N/A
5/7/2026	Q1 2026	HRMY Harmony Biosciences	$0.76	$0.55	-$0.21	$0.55	$220.84 million	$215.39 million
5/7/2026	Q1 2026	IOVA Iovance Biotherapeutics	-$0.19	-$0.19	N/A	-$0.19	$77.84 million	$71.43 million
5/7/2026	Q1 2026	RAPP Rapport Therapeutics	-$0.56	-$0.42	+$0.14	-$0.42	$7.50 million	$20.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRMY Harmony Biosciences	0.15	3.58	3.56
IOVA Iovance Biotherapeutics	N/A	3.60	3.15
NGNE Neurogene	N/A	13.08	13.08
RAPP Rapport Therapeutics	N/A	27.08	27.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRMY Harmony Biosciences	86.23%
IOVA Iovance Biotherapeutics	77.03%
NGNE Neurogene	52.37%
RAPP Rapport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
HRMY Harmony Biosciences	11.00%
IOVA Iovance Biotherapeutics	7.80%
NGNE Neurogene	11.68%
RAPP Rapport Therapeutics	12.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRMY Harmony Biosciences	200	57.89 million	51.53 million	Optionable
IOVA Iovance Biotherapeutics	500	446.50 million	411.68 million	Optionable
NGNE Neurogene	90	15.80 million	13.96 million	Optionable
RAPP Rapport Therapeutics	N/A	47.83 million	41.86 million	N/A

NGNE, HRMY, IOVA, and RAPP Headlines

Recent News About These Companies

Abraham Ceesay Sells 2,210 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

July 30 at 6:36 AM | insidertrades.com

Rapport Therapeutics (RAPP) to Post Quarterly Earnings on Thursday

July 30 at 3:40 AM | marketbeat.com

William Blair Initiates Coverage on Rapport Therapeutics (NASDAQ:RAPP)

July 30 at 1:36 AM | americanbankingnews.com

Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $93,063.10 in Stock

July 29, 2026 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Hits New 52-Week High - Here's Why

July 28, 2026 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Earns Outperform Rating from Analysts at William Blair

July 28, 2026 | marketbeat.com

Siren L.L.C. Lowers Stock Holdings in Rapport Therapeutics, Inc. $RAPP

July 24, 2026 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Hits New 12-Month High - Should You Buy?

July 20, 2026 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.4% - Time to Buy?

July 17, 2026 | marketbeat.com

Rapport Therapeutics' (RAPP) Buy Rating Reaffirmed at BTIG Research

July 16, 2026 | marketbeat.com

Candriam S.C.A. Invests $5.82 Million in Rapport Therapeutics, Inc. $RAPP

July 14, 2026 | marketbeat.com

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 13, 2026 | marketbeat.com

What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?

July 12, 2026 | fool.com

Y Intercept Hong Kong Ltd Makes New $1.12 Million Investment in Rapport Therapeutics, Inc. $RAPP

July 12, 2026 | marketbeat.com

Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?

June 16, 2026 | insidermonkey.com

Rapport Therapeutics Holds 2026 Annual Shareholder Meeting

June 10, 2026 | tipranks.com

Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?

June 8, 2026 | finance.yahoo.com

BTIG Raises its Price Target on Rapport Therapeutics (RAPP)

June 6, 2026 | finance.yahoo.com

RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy

June 4, 2026 | tipranks.com

Rock Ventures L.P. Third Sells 18,572 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

May 29, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE, HRMY, IOVA, and RAPP Company Descriptions

Harmony Biosciences NASDAQ:HRMY

$35.24 -0.62 (-1.73%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$35.28 +0.04 (+0.11%)

As of 07/31/2026 07:34 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Iovance Biotherapeutics NASDAQ:IOVA

$4.07 -0.62 (-13.22%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.09 +0.02 (+0.49%)

As of 07/31/2026 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Neurogene NASDAQ:NGNE

$32.89 -0.71 (-2.11%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$32.92 +0.02 (+0.08%)

As of 07/31/2026 07:34 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Rapport Therapeutics NASDAQ:RAPP

$40.98 -1.80 (-4.21%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$41.05 +0.07 (+0.17%)

As of 07/31/2026 07:34 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NGNE, HRMY, IOVA, and RAPP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NGNE, HRMY, IOVA, and RAPP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NGNE, HRMY, IOVA, and RAPP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE, HRMY, IOVA, and RAPP Company Descriptions

Harmony Biosciences NASDAQ:HRMY

Iovance Biotherapeutics NASDAQ:IOVA

Neurogene NASDAQ:NGNE

Rapport Therapeutics NASDAQ:RAPP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NGNE, HRMY, IOVA, and RAPP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NGNE, HRMY, IOVA, and RAPP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NGNE, HRMY, IOVA, and RAPP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE, HRMY, IOVA, and RAPP Company Descriptions

Harmony Biosciences NASDAQ:HRMY

Iovance Biotherapeutics NASDAQ:IOVA

Neurogene NASDAQ:NGNE

Rapport Therapeutics NASDAQ:RAPP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools